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Abstract: Objective: To review the scientific literature that has verified and/or assessed compliance
and adherence to enteral nutrition (EN) in adult patients. Method: This study involved a critical
analysis of articles retrieved from MEDLINE (PubMed), The Cochrane Library, Embase, Scopus and
Web of Science using the terms “Treatment Adherence and Compliance” and “Enteral Nutrition”,
applying the filters “Comparative Study” or “Clinical Trial”, “Humans” and “Adults”. Date of the
search: 25 October 2018. Results: A total of 512 references were retrieved, of which 23 documents
were selected after applying the inclusion and exclusion criteria. The techniques measuring adherence
to EN were determined by dietary intake, self-reporting, counts of leftover containers or presence of
complications; however, in no case were validated questionnaires used. The time and periodicity of
the assessment presented very heterogeneous results, with measurement predominantly being done
at the beginning and at the end of the study. The best adherence rates were obtained in hospitalized
patients (approximately 80%). Conclusions: Frequent and regular monitoring of the adherence of
patients under prolonged treatment with EN is necessary, and the use of measurement techniques
that allow obtaining information on the causes of non-adherence facilitates early interventions to
optimize treatment outcomes. Patient and/or caregiver education in the management of EN and
the intervention of the community pharmacy in monitoring patients can be key to improving the
adherence to EN.
Keywords: treatment adherence and compliance; enteral nutrition; attitude to health; nutritional
support; adult
1. Introduction
Enteral nutrition (EN) is a treatment consisting of administering, through the digestive tract,
nutrients necessary to maintain an adequate nutritional status in patients who cannot meet their
nutritional needs orally due to their clinical situation but whose digestive tract still functions for
digestion and absorption [1]. However, the efficacy of this nutrition is determined by several factors:
some are intrinsic to the treatment itself, others are derived from the disease and other are determined
by adherence behavior [2].
Concern about adherence gained importance in the second half of the 20th century, when advances
in the health sciences made treatments safer and more effective; however, lack of compliance continued
to lead to unresolved indications and the appearance of concomitant problems [2]. This complex
situation continues to be a current problem, probably because in recent years, there has been a
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progressive increase in the incidence of chronic diseases that lead to the the coexistence of simultaneous
treatments in the same patient for a prolonged period [3].
The concept and definition of adherence have been widely discussed, which is why the World
Health Organization (WHO) [4] issued, in 2003, a report on “Adherence to long-term therapies”, which
showed that the definition considered until then was strictly focused on adherence to pharmacological
treatment or medical indications and did not include any other type of intervention or recommendation
regarding changes in lifestyle (hygiene, exercise, nutrition, etc.), leaving out a large number of patient
behaviors that compromised the evolution of their pathology and their well-being. Therefore, the
WHO proposed in the Adherence Project [5] to update the concept as “The extent to which a person’s
behavior—taking medication, following a diet, and/or executing lifestyle changes, corresponds with
agreed recommendations from a health care provider”.
According to the Medical Subject Headings (MeSH) of the US National Library of Medicine
(NLM), the definition for “Treatment Adherence and Compliance” would be: the extent to which the
patient follows prescribed treatment such as keeping appointments and schedules and medication
adherence for desired therapeutic outcome. It implies active responsibility shared by patient and
health care providers (NLM MeSH Homepage: https://www.ncbi.nlm.nih.gov/mesh).
The American and European societies of enteral and parenteral nutrition showed, in their clinical
guidelines, the existence of discrepancies between the amounts prescribed and those received by
patients who were administered artificial nutrition with feeding tubes [6,7]. Van den Broek et al. [8],
in a study in a hospital setting, assessed adherence during the admission period. Although these
results can be considered an approximation for assessing adherence, it cannot be assumed that there is
a real, or even approximate, vision of what happens with patients who have had EN prescribed for a
long time, especially in the home environment, where the controls, registries, pumps, dedication and
interest in complying with the established nutritional regimen is, undoubtedly, highly variable [2].
Consequently, the objective of this study was to review the scientific literature that has verified
and/or assessed compliance and adherence to EN in adult patients.
2. Materials and Methods
2.1. Design
Cross-sectional descriptive study and critical analysis of the works systematically retrieved.
2.2. Source of Data Collection
The data were obtained from direct consultation and access, via the Internet, to the following
bibliographic databases in the field of health sciences: MEDLINE (via PubMed), The Cochrane
Library: The Cochrane Central Register of Controlled Trials (CENTRAL) and The Cochrane Database
of Systematic Reviews (CDSR), Embase, Scopus and Web of Science.
2.3. Information Search
To define the search terms, the thesaurus developed by the US National Library of Medicine was
referred to.
The search strategy was planned around three domains:
- Population: adults with an age equal to or greater than 19 years;
- Intervention: EN;
- Outcome: known compliance and adherence to treatment and the method used for its assessment.
For this, the search syntax was generated using the Boolean intersection of two equations:
(Equation (1)) and (Equation (2)).
Equation (1): Treatment Adherence and Compliance.
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“Treatment Adherence and Compliance” [Mesh] OR “Treatment Adherence and Compliance”
[Title/Abstract] OR “Patient Acceptance of Health Care” [Title/Abstract] OR “Patient Compliance”
[Title/Abstract] OR “Patient Dropouts” [Title/Abstract] OR “Patient Participation” [Title/Abstract]
OR “Patient Satisfaction” [Title/Abstract] OR “Patient Preference” [Title/Abstract] OR “Treatment
Refusal” [Title/Abstract] OR “Patient Acceptance of Health Care” [Title/Abstract] OR “Patient Dropouts”
[Title/Abstract] OR “Patient Adherence” [Title/Abstract] OR “Patient Cooperation” [Title/Abstract]
OR “Patient Non-Compliance” [Title/Abstract] OR “Patient Non Compliance” [Title/Abstract] OR
“Patient Nonadherence” [Title/Abstract] OR “Patient Noncompliance” [Title/Abstract] OR “Patient
Non-Adherence” [Title/Abstract] OR “Patient Non Adherence” [Title/Abstract] OR “Treatment
Compliance” [Title/Abstract] OR “Treatment Compliances” [Title/Abstract] OR “Therapeutic
Compliance” [Title/Abstract] OR “Therapeutic Compliances” [Title/Abstract]
Equation (2): Enteral Nutrition.
“Enteral Nutrition” [Mesh] OR “Enteral Nutrition” [Title/Abstract] OR “Enteral Feeding”
[Title/Abstract] OR “Force Feeding” [Title/Abstract] OR “Force Feedings” [Title/Abstract] OR “Tube
Feeding” [Title/Abstract] OR “Gastric Feeding Tubes” [Title/Abstract] OR “Gastric Feeding Tube”
[Title/Abstract].
The following filters were applied: “Humans”, “Adult 19+ years” and “Comparative Study” or
“Clinical Trial”.
The final search equation was developed for use in the MEDLINE database, via PubMed.
Subsequently, this strategy was adapted to the characteristics of each of the other databases consulted
and was completed by examining the bibliographic references of the selected articles.
The search was performed from the first available date until the day of the last query of the
databases (initial search in MEDLINE 25 October 2018).
Additionally, a search using a complementary strategy was conducted to reduce the possibility
of publication bias by searching the reference lists of relevant guidelines. Furthermore, experts in
the domain were contacted by mail to avoid issues regarding possible grey literature (materials and
research produced by organizations outside of the traditional commercial or academic publishing and
distribution channels).
2.4. Final Selection of Articles
The records that met the following inclusion criteria were accepted for review: clinical trials or
comparative studies that fit the objectives of the search and were published in peer-reviewed journals.
A selection of references first based on title/abstract and after on full-text review was performed.
Articles were screened based on the availability of the complete text, the existence of a causal relationship
between treatment adherence and EN, and the inclusion of adults in the intervention (EN). Any article
that did not meet these criteria was excluded.
The selection of relevant papers was performed independently by two authors: A.G.C. and
E.L.P. To include the studies, it was established that the valuation of the concordance between these
authors (kappa index) must be greater than 60% [9]. Provided this condition is fulfilled, possible
discrepancies were solved through consultation with the author J.S.V. and subsequent consensus
amongst all the authors.
2.5. Quality of Reporting of the Selected Documents
To assess the quality of reporting of the selected documents, the CONSORT (Consolidated
Standards of Reporting Trials) statements were used [10]; the checklist contains a list of 25 essential
aspects that should be described in the studies. One point was assigned for each item present (if not
applicable, it was not scored). When an item was composed of several points, the points were assessed
independently, giving the same value to each point and then averaging them (the final result of that
item), so that in no case was it possible to score more than 1 point per item.
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2.6. Obsolescence
To inform of the actuality/obsolescence of the clinical trials selected for the review, the Burton-Kebler
half-life (median age) and Price Index (percentage of articles less than 5 years old) were calculated.
2.7. Data Extraction
Continuous control for data correction was ensured by using double-entry charts that allowed
deviations to be detected and corrected by making a new query of the originals. Data extraction was
carried out independently by A.G.C. and E.L.P., and M.S.L. was responsible for the verification of
the tables.
2.8. Study Variables
• The studies were grouped according to the variables studied to systematize and facilitate the
interpretation of the results, considering the following data:
• Author: the first author of the article was selected;
• Year: year of publication of the article;
• Design: procedures, methods and techniques through which the article was accepted for review.
In this case, only clinical trials or comparative studies were accepted;
• Population studied: Adults undergoing EN intervention;
• Country: location where the intervention took place;
• Pathology: disease of the population for which the intervention was performed;
• Type of nutrition: if total/exclusive enteral nutrition (EEN), when the only source of food is
formula-based, or partial (PEN);
• Form and frequency of administration: route through which EN was administered and
its periodicity;
• Technique for measuring adherence: procedure used to determine adherence to EN;
• Outcome observed: causal relationship derived from the intervention (administration of EN).
3. Results
With the described search criteria, 512 references were retrieved: 53 in MEDLINE, 71 in the
Cochrane Library, 47 in Embase, 43 in the Web of Science and 298 in Scopus.
After eliminating duplicates, applying the inclusion and exclusion criteria, consulting the
bibliographies of the selected articles and consulting with experts (Figure 1), 23 documents were
selected [11–33] (Table 1). Two articles by Brown et al. [15,34] were selected; although they presented
different objectives of study, the population analyzed was the same, and adherence results were not
different between them, and therefore, only one was accepted for review [15].
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Figure 1. Selection procedure of the studies.
There were two studies that were initially included in the review [35,36], but after careful review
of their content, patient compliance with EN had not been assessed. Goh et al. [35] assessed adherence
to the recommended initiation of EN in Parkinson’s patients at risk of dysphagia, without providing
compliance data. Peerawong et al. [36] studied adherence to radiation therapy and chemotherapy
in patients with prophylactic gastrostomy tubes; however, they did not assess adherence to EN
treatment during the 52-day monitoring period. Because the two aforementioned investigations were
retrospective studies, information on adherence was probably available. This lack of knowledge on
adherence could lead to an underestimation of treatment effects.
When evaluating the quality of the selected articles using the CONSORT questionnaire, the scores
varied between 7 and 21 (compliance with 25 of 28 items, or 84%), with a median of 11.5 (see Table 2).
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Table 2. Assessment of study quality according to the 25-item CONSORT guidelines.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Total
Hirai et al. 2019 [11] 0.5 1 0.5 1 0 0.5 0.5 0 0 0 0 0.5 0.5 0.5 1 1 0.5 0 1 1 0 1 0 0 0 728%
Wall et al. 2018 [12] 0.5 1 0 1 1 0.5 0 0 0 0 0 0.5 1 0 1 1 0.5 0 1 1 1 1 0 0 1 1144%
Benton et al. 2018 [13] 0.5 1 1 1 1 0.5 0.5 0.5 0 0 0 0.5 1 0 1 1 0.5 1 0 1 0 1 0 0 1 1144%
Deane et al. 2018 [14] 1 1 0.5 0.5 1 0.5 0 1 0 0 0.5 0.5 1 0.5 1 1 0.5 0 1 1 0 1 0 1 0 1144%
Brown et al. 2017 [15] 0.5 1 0 0 1 0 0 0 0 0 0 0.5 1 0.5 1 1 0.5 0 1 1 0 1 0 0 1 936%
Healy et al. 2017 [16] 0 0.5 0 1 1 0.5 0.5 1 0 0 0.5 0.5 1 0.5 1 1 0.5 0 1 0 0 1 0 0 0 11.546%
Harvey et al. 2016 [17] 1 1 0.5 1 1 0.5 1 1 1 1 0.5 1 1 0.5 1 1 0.5 1 1 1 1 1 1 1 1 2080%
Zhao 2015 [18] 0.5 0.5 0 0.5 1 0.5 0 0 0 0 0 0.5 0 0 0 0 0.5 0 1 0 1 1 0 0 0 728%
Stow et al. 2015 [19] 1 1 0.5 1 1 0.5 0.5 1 1 1 0.5 0.5 1 1 1 1 0.5 0 1 1 1 1 1 1 1 2184%
Hamza et al. 2015 [20] 1 1 0.5 0.5 1 0.5 0.5 1 0 0 0 1 1 0 1 1 0.5 0 0 1 0 1 0 0 0 12.550%
Bowrey et al. 2015 [21] 1 1 0.5 0.5 0 1 0.5 1 0 0.5 0 0.5 1 0.5 1 1 0 0 1 0 1 1 0 0 1 1456%
Sukkar et al. 2013 [22] 0 1 0 0.5 1 0.5 0 0 0 0 0.5 0.5 1 0.5 1 0 0.5 0 1 0 1 1 0 1 1 1248%
Shirakawa et al. 2012 [23] 0.5 1 0 0.5 1 0.5 0 0 0 0 0 0.5 0.5 0.5 1 1 0.5 0 1 0 1 1 0 0 0 11.546%
Sadasivan et al. 2012 [24] 0 1 1 0.5 1 0.5 0.5 1 0 0 0 0.5 1 0.5 1 1 0.5 0 1 1 0 1 0 0 0 1352%
Kraft et al. 2012 [25] 0 1 0.5 0.5 1 0.5 0.5 0.5 0 0 0 0 1 0.5 1 1 0 0 0 0 1 1 0 0 1 1144%
Miyata et al. 2012 [26] 1 1 0 0.5 1 0.5 0 0.5 0 1 0 0.5 1 0.5 1 1 0.5 0 1 1 0 1 0 0 1 1456%
Pohl et al. 2009 [27] 1 0.5 0.5 1 1 0.5 0.5 0.5 1 1 1 0.5 1 1 1 1 1 0 1 1 1 1 0 0 0 1872%
Takagi et al. 2006 [28] 1 1 0 1 1 0.5 0.5 1 1 1 0.5 0.5 1 1 1 1 0.5 0 1 1 1 1 0 0 0 17.570%
McGough et al. 2006 [29] 0.5 1 0.5 1 1 0.5 0.5 1 1 1 0 1 0.5 0 1 1 0 1 1 0 1 1 0 0 1 16.566%
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Table 2. Cont.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Total
Piquet et al. 2002 [30] 0 1 0 0 1 0.5 0 0 0 0 0 0.5 0.5 0.5 1 1 0.5 0 1 0 1 1 0 0 0 9.538%
Tsujikawa et al. 2000 [31] 0 1 0 1 1 0.5 0 0 0 0 0 0.5 0 0 0 0 0.5 1 0 1 0 1 0 0 0 7.530%
Lawson et al. 2000 [32] 0.5 1 0 1 1 0 0 0 0 0 0 0.5 0.5 0 0 0 0.5 0 1 0 0 1 0 0 0 728%
Park et al. 1992 [33] 1 0.5 0.5 1 1 0.5 0.5 0.5 1 0 0 1 1 1 1 1 0.5 1 1 0 1 1 0 0 1 1768%
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The agreement between authors in the selection of articles, measured by the Kappa coefficient,
was 70.85% (p < 0.001). Twenty-three articles presented obsolescence, according to the Burton-Kebler
Index, being 6 years old, with a Price Index of 47.83%.
Study design included seven comparative studies [11,13,22,23,25,30,31] and 16 clinical
trials [12,14–21,24,26–29,32,33], all written in English and developed in 10 different countries, with the
United Kingdom [17,19–21,29,32,33] and Japan [11,23,26,28,30,31] contributing the most work.
The articles studied a highly variable number of participants, from n = 1197 [17] to n = 22 [22],
focused predominantly on males according to the male/female ratio. The average age was approximately
60 years in most studies, except for the studies by Hirai et al. [11] and Wall et al. [12] with patients
with Chron’s disease, who were approximately 20 years old. The most common underlying pathology
was neoplasia, nine studies [15,16,20,21,23,24,26,29,30], and most of the research was carried out in a
nonhospital setting (non-hospitalized patients, PNH), 16 studies [11–13,15,16,19,21,22,24–31].
The longest recruitment period was that of the study by Healy et al. [16], from January 2011 to
December 2014. The longest monitoring time was that of the study by Hirai et al. [11], which was
2 years.
Regarding EN type, 11 studies involved partial enteral nutrition
(PEN) [11,13,15,16,19,21,23,25,28,29,32], five studies involved exclusive enteral nutrition
(EEN) [14,18,24,27,33] and seven studies involved different combinations of PEN and
EEN [12,17,20,22,26,30,31].
In 10 studies, the main route of administration was through a tube (gastrostomy, nasogastric,
jejunostomy, etc.) [13–15,17,18,21,22,24,27,33]; in seven studies, the route was either oral or
through a feeding tube [11,16,20,23,26,28,30]; and in six articles, the route was exclusively
oral [12,19,25,29,31,32]. However, the choice of administration form depended on the underlying
pathology [11,12,21,22,24,27–31,33,35], the treatment (e.g., chemotherapy) [15,16,26,36], prior
surgery [13,15,20,23,32] and individualized patient requirements [14,17–19,25].
3.1. Adherence Measurement Methods
Adherence was assessed by measuring intake in 15 of the 23 articles included. Intake
was determined by dietary intake, self-reported intake of nutrients or energy by the patients
themselves [12,13,15,16,20,21,25,29] or directly by the project staff [17,19,23,32]. Two studies [26,30]
measured the consumption of kcal and protein without indicating the form of administration, and Hirai
et al. [11] related adherence with continuing with the prescribed amount (versus amount ingested)
during the study period.
In eight studies [14–16,19,20,29,32,33], adherence was assessed based on the number of containers
returned by the patient (or self-reported intake) and the number of prescribed containers: (containers
returned or reported as ingested/prescribed containers) * 100.
In 14 studies [12,13,16,17,19–26,30,33], markers of nutritional status and/or anthropometric
parameters were assessed as measures of the outcome of the interventions. Other studies [18,22,24,27,28]
assessed the presence of mechanical complications of EN and/or gastrointestinal side-effects of EN
adherence, such as nausea, vomiting or diarrhea, an aspect also recorded in studies [11,12,14–16,21].
Finally, in four of the included studies, patients received education about EN (dietary advice and/or
feeding tube management and nutritional supplements) at the beginning of the investigation [21,22,28,31].
3.2. Periodicity and Time of Measuring Adherence
Regarding the timing and periodicity with which adherence was assessed, the results are very
heterogeneous. Benton et al. [13] and Sukkar et al. [22] performed two single measurements, one at the
beginning and one at the end of the study. In the rest of the studies, there was very variable monitoring,
from daily to weekly or with a periodicity of up to 6 months.
In nine studies, daily measurements of compliance with EN by the patient were performed;
six of the studies were performed with hospitalized patients with a monitoring period of less than
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1 month [14,17,18,20,23,33]. The studies by Miyata et al. [26] and McCough et al. [29] were performed
with non-hospitalized patients, with adherence monitored for 17 days and 5 weeks, respectively.
In the study by Kraft et al. [25], monitoring of adherence was carried out daily for 6 months through
telematic means.
In general, studies with monitoring periods of 3 or more months [11,16,19,21,24,28] recorded
measurements every 2 [11] or 3 months [19,28], or recorded two measures close together: one
at the beginning and one in the first weeks, and the next at 6 months [21,24]. Brown et al. [15],
performed [12,16,30,32] weekly measurements for 3 months.
Studies less than 3 months long [12,16,30,32] recorded measurements weekly [32], every
2 weeks [12,30] or at 1 month [16].
3.3. Adherence Rates and/or Compliance with EN Protocols
In 11 of the studies reviewed [11–17,19,23,30,33], quantitative data were provided on the rate of
adherence to EN or the degree of compliance with the established EN protocol.
In general, studies measuring the adherence of hospitalized patients to EN [14,16,17,23,30,33]
presented rates above 80%, with the exception of Lawson et al. [32], who obtained a median compliance
of 14.9% in patients undergoing orthopedic surgery who were followed for 14 days, noting that none
of the patients were 100% adherent, taking half of the prescribed volume in half of the indicated time,
and that during monitoring, 76% of the patients made some readjustment in the type of supplement to
adapt it to their preferences.
In the studies performed with non-hospitalized patients, the adherence rates were lower. In the
studies by Hirai et al. [11], Wall et al. [12], Benton et al. [13] and McCough et al. [29], adherence did not
reach 50%. Brown et al. [15], in their clinical trial conducted in patients with head and neck cancer,
found an adherence rate of 51% in patients who were introduced to EN in the early (prophylactic)
phase, highlighting the progressive increase in adherence in the first 4 weeks, which they justified as a
period of adaptation to the feeding tube. Stow et al. [19], in a controlled clinical trial conducted with
patients at risk of severe malnutrition living in adult care homes, found 74% adherence at 3 months
and 67% at 6 months, where 86% of patients met at least 50% of the requirements.
The work by Hamza et al. [20] and Bowrey [21] assessed EN ingestion but did not provide data
on adherence. Takagi et al. [28] indicated that adherence was similar between the compared groups
but did not specify how and when it was assessed. Sukkar et al. [22] only recorded complications in
the maintenance of the feeding tube, without monitoring compliance with EN; however, they found
that 9% of patients abandoned treatment due to low compliance.
Healy et al. [16], Zhao [18], Sadasivan et al. [24] and Tsukikawa et al. [31] assessed patient
satisfaction and/or quality of life, both variables related to adherence.
4. Discussion
The present review demonstrated, in one way or another, the special interest in knowing
compliance and adherence to nutritional treatment.
Considering that both clinical trials and comparative studies have been included in this review,
it is likely that the CONSORT questionnaire was not the most suitable for evaluating the quality of
articles with comparative designs, which is why the value obtained in the results was not as high
as expected for rigorous studies. Although systematic reviews should be based on studies with
monitoring protocols and designs that guarantee the greatest scientific rigor, in the present analysis,
all articles investigating the analyzed topic were included to achieve maximum representation in the
results. Restricting the review to clinical trials and comparative studies was decided so as to search for
a consistent cause-effect relationship [37].
The low obsolescence of the studies included in the review indicated the validity and timeliness as
well as the interest in the chosen topic; the data obtained (Price Index and Burton Kebler index) indicate
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lower obsolescence than the usual bibliometric results in the field of nutrition sciences, demonstrating
that this is a newly emerging area [38].
The language of the included studies was as expected, with all papers analyzed written in English.
This language is preferred for the publication of the majority of articles because publication in a
different language decreases visibility, the impact factor and citations. In addition, the number of
anglophone journals contained in the databases is currently very high [39].
The population included in the studies was notably older, mainly because the pathology with
the greatest presence was neoplasia, mainly treated in the home setting, where studies related to this
circumstance already exist [1].
The recruitment and monitoring periods were considered adequate and consistent with what was
observed in previous systematic reviews [37], a requirement that the selected studies met except for
the articles by Deane et al. [14], Harvey et al. [17], Zhao [18] and Shirakawa et al. [23], whose study
durations were too short to adequately assess pharmacotherapy-therapeutic monitoring. However,
as has been investigated, nutrition monitoring of patients was directly related to improvements in
nutritional status [40].
The clear predominance of PEN over EEN followed the recommendations of the different clinical
guidelines, which clearly state that before establishing enteral treatment, the possibility of consuming
normal foods (natural, prepared or processed) should be assessed. If this is not possible, enteral
formula-based foods should be used. Only in clinical situations where the oral route was compromised
was EEN chosen [41,42]. These same recommendations served as the basis of choosing the route
of EN administration; however, the form of administration depended, as seen in the results, on the
underlying pathology and its treatment (e.g., chemotherapy) and on individual patient requirements.
4.1. Adherence Measurement Methods
In the majority of the studies reviewed, the assessment of adherence to EN was performed by
indirect techniques, such as dietary intake (self-report of intake by the patient) or the number of leftover
containers and its relation with the prescribed number provided. Both techniques offer an approximation
of an individual’s behavior regarding medication. However, according to Lehmann et al. [43], these
procedures have limitations. In principle, the questionnaires used to measure intake should be
validated. Wall et al. [12] used electronic self-reporting of intake by the patient to evaluate adherence,
recognizing as a bias that the questionnaire was not validated in adults. In the rest of the studies, no
details on the validation of the tool used were provided. Furthermore, the amount that the patient
claims to ingest may be influenced by forgetfulness or be distorted, especially if recorded by someone
other than the patient, for example, the caregiver [44], or by a lack of trust in the relationship between
the patient and the healthcare professional. The count of leftover containers, meanwhile, is a static
measure that does not reflect the daily variability of adherence. There are also risks of false positives
due to patients emptying the containers before returning them, which is common if the patient feels
watched [43].
Lack of adherence can be due to multiple causes, such as the presence of barriers or beliefs of
the patient, ignorance and forgetfulness or carelessness [45]. The multifactorial nature of the problem
means that there is no ideal method for measuring adherence. Therefore, to increase the validity
and reliability of the adherence data collected, combining more than one technique is recommended
depending on the information desired from the patient. In this sense, the questionnaires, despite their
limitations, constitute the simplest method and are used both in research and epidemiological studies
and in clinical practice due to their simplicity, ease of application and ability to guide toward the
possible cause of lack of adherence [43]. A relevant fact detected in this review is that none of the
studies evaluated used specific questionnaires to measure adherence to EN, such as that proposed by
Wanden-Berghe et al. [2]. If in more than half of chronic patients this type of nutrition is prescribed [46],
it seems reasonable to have a validated instrument that allows for managing nutritional adherence.
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In the majority of the studies, the anthropometric and biochemical parameters and nutritional
state of the patient were assessed. These results are usually part of the routine monitoring of patients
treated with EN [41,42]; however, their use as surrogate markers of adherence is limited because they
can be affected by other factors, not only by the behavior of the patient but also by the adequacy of
medication and biological, genetic or environmental factors [43].
Additionally, some studies used the presence of mechanical complications of EN and/or
gastrointestinal side-effects (nausea, vomiting or diarrhea) as indicators of adherence. These problems
are also frequently monitored in patients with EN [47] and are related to the tolerability of the formula,
and while their appearance may cause treatment withdrawal, they may not be the only cause of
non-adherence. In addition, good tolerance does not guarantee patient adherence, and therefore, should
not exempt the need to monitor adherence. Although several of the studies reported complications and
adverse effects, it is noteworthy that for only four patients were the patient and/or caregivers previously
educated and trained in the management of EN. This fact is relevant; EN may entail “complex” drugs,
which are those whose use requires special skills by the patient and may be a potential source of error,
such as inhalers [48]. In this type of treatment, as in EN, adherence is influenced by multiple factors
(complexity of the delivery devices, administration guidelines, patient beliefs or sociocultural factors),
and patients or their caregivers should be educated to maximally reduce complications and facilitate
their independence and self-sufficiency as much as possible [41]. In this sense, patient empowerment
is a key element to improving adherence [49].
4.2. Periodicity and Time of Measuring Adherence
Compliance monitoring was carried out with a highly variable periodicity, from studies where
monitoring was performed daily to others that conducted weekly monitoring or with a periodicity of
up to 6 months.
If the studies lasting less than 3 months are eliminated and those conducted in inpatients where
controls were more frequent and, often, the professionals administered EN, the remainder of studies
assessed adherence with less frequency: every 2–3 or even 6 months, with no interventions to improve
adherence. This would explain the low adherence rates found in some studies. This periodicity
coincides with the minimum frequency of 3 months with which it is recommended that EN be
assessed [41,42].
However, therapeutic adherence has a dynamic behavior, probably less stable than nutritional
status or biochemical parameters, which means that it must be reevaluated with a certain frequency
to prevent possible variations over time. Gearing et al. [50] proposed up to six phases of adherence
to treatment: initiation, trial, partial acceptance, intermittent treatment adoption, premature
discontinuation and total adherence.
Kraft et al. [25] carried out a comparative study in patients at risk of severe malnutrition, where
monitoring was performed telematically daily for 6 months. The authors did not present adherence
figures; however, this system made it possible to receive alerts such as that the patient “has not taken the
oral nutritional supplement”, “did not like the taste of the oral nutritional supplements” or “took only
a little bit”. In this sense, “telehealth” and the use of telematic means is a way of maintaining regular
contact with health professionals and facilitating the monitoring of adherence to prescribed treatments
by collecting vital signs and data on intake and sharing information among patients, caregivers and
professionals involved so that everyone has access to information in real time [51], thus allowing the
implementation of early interventions. In any case, the limitations of this form of EN monitoring
should be assessed because the authors reported difficulties in recruiting patients in the study because
they did not understand the importance of monitoring EN or were not familiar with electronic devices.
In any case, there is no ideal frequency of measurement, but the ideal time to assess adherence
would be the moment when this type of treatment is dispensed in chronic non-hospitalized patients.
Evaluating how patients’ pattern of use departs from the methodology of dispensation would detect
situations of non-adherence and allow for interventions to improve adherence [52]. In this sense, the
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community pharmacist is in the ideal position to carry out this task [53]. A recent systematic review
and meta-analysis of 771 articles on adherence interventions published in 2017 suggested that the most
effective interventions are those performed face-to-face with the patient and by pharmacists [54]. There
are other studies that support the contribution of community pharmacists to improving adherence [55].
Therefore, the community pharmacist could take on the role of being responsible for adherence
monitoring in each dispensation, that is, approximately once a month.
4.3. Adherence Rates and/or Compliance with EN Protocols
In relation to the adherence rates found, the results of this review showed a clear differentiation
between studies conducted in a hospital setting and those conducted with non-admitted patients,
with influence in both cases of patient monitoring time. The best adherence rates, above 80%, were
obtained in hospitalized patients and in short monitoring studies, such as those by Deane et al. [14],
Healy et al. [16], Harvey et al. [17], Shirakawa et al. [23] and Park et al. [33]. This is probably because
patients are better managed by professionals in a hospital environment where monitoring is simpler
and is usually part of routine practice, something that also occurs when the patient is in an adult care
home, as demonstrated by Stow et al. [19], who obtained adherence rates greater than 70%.
Lawson et al. [32], on the contrary, constitute the exception, finding an adherence rate lower than
15%. The explanation for this low adherence in the hospital setting could be due to the method of
intensive monitoring of adherence, probably the most exhaustive of all the studies reviewed: the
patient had to sign when given the supplement or if it had been rejected and the reason; the patients,
nurses and staff recorded the amount ingested for each supplement; dietitians completed a weekly
review; discussions regarding progress were held with the patient; total supplements ingested and/or
rejected were recorded; and patients self-reported the food and beverages consumed outside of hospital
catering. Through this methodology, the authors were able to accurately evaluate the adherence
of each patient, calculate the volume consumed for each container and the time during which the
instructions were followed, and determine the patient’s willingness to make changes regarding the
type of supplement and record discontinued treatment mutually decided upon by the patient and
professional. These results showed that in EN monitoring, the patient’s preferences should be taken
into account, as the benefit of nutritional supplementation depends on the acceptance and compliance
of patients.
In contrast, when the patients were at home, the situation changed. The pattern of adherence
observed in non-hospitalized patients with a monitoring period of 3 months or more was similar to
that of patients with chronic pharmacological treatments, where adherence was less than 50% [4],
altering the outcome of the interventions. Thus, Hirai et al. [11] found no significant differences in the
remission rate of Crohn’s disease between control and intervention groups, attributing this result to the
lack of adherence to EN by the intervention group, where only 11/37 patients met the prescribed caloric
requirements. Brown et al. [15] obtained a 51% adherence rate, which was lower than expected, in
patients in whom early intubation was initiated. However, patients in this group were more adherent
than those in the control group once treatment started (58% versus 38%), resulting in less significant
weight loss in patients from the intervention group, which the authors attributed to greater adherence.
Furthermore, Wall et al. [12] found an EN protocol abandonment rate close to 40%, and Benton
et al. [13] found that less than 50% of patients with jejunostomy met predefined caloric and protein
requirements at 42 days of treatment. McGough et al. [29], in patients with gynecological cancer, found
a progressive decrease in adherence over time, decreasing from 92% in week 1 to 46% in week 5, a
downward progression that was also reflected in the studies by Stow et al. [19]. These data agree with
what has been described for chronic pharmacological treatments, where it was estimated that during
the first year, 1 in 2 patients discontinues treatment [56] or there is a progressive loss of adherence until
the patient accepts the treatment and becomes familiar with it [57]. In the case of EN, in addition, the
use of a feeding tube requires a period of adaptation, as suggested by Brown et al. [34].
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The high adherence found by Piquet et al. [30] (close to 80%), was attributed to the fact that
nutritional support was proposed very early by medical staff as an additional component of treatment.
This is another important point. The lack of consideration of EN by patients and/or caregivers as part
of the success of treatment may lead to relativizing its usefulness and thus compliance, a fact also
discussed by Kraft et al. [25]. The professionals involved should educate patients that EN is not simply
a food but that its consumption can help achieve the expected positive treatment outcomes.
4.4. Limitations of the Review
The Scopus database initially retrieved many works that were ultimately irrelevant, which could
be due to the lack of indexing (the search was done in text format querying the title, abstract and
keywords) and the impossibility of limiting the search by the type of article (restricted to clinical trials
or comparative studies). This high document “noise” was previously observed in other systematic
reviews [58,59]. Another important limitation of the present review was not being able to retrieve the
full text of some articles because they were not digitized on the journal’s website or did not appear
in the main journal collections and even could not be retrieved through the network of university
libraries. Finally, with regard to the adherence results, it would have been interesting to summarize
them by a quantitative value or to give a measure of central tendency; however, the few papers showing
data regarding the percentage of adherence and the great heterogeneity in the different adherence
measurement techniques hindered this calculation.
4.5. Critical Review by the Authors
Knowing the degree of adherence of patients is essential to evaluate the effectiveness and safety
of treatment with EN. Currently, there is not an established adherence rate in EN that guarantees a
therapeutic outcome, which means that patient achieve their nutritional needs; however, in accordance
with Apolo et al. [60], we would consider an acceptable adherence rate the compliance of at least
70% of individual requirements. EN, due to its characteristics and complexity of management, could
be compared to chronic treatment, which requires special monitoring and patient education in its
management and where adherence should be reevaluated with a certain frequency to prevent possible
variations over time, especially in patients not hospitalized for prolonged treatment. Increasing the
periodicity of monitoring in combination with intake assessments and using specific questionnaires to
detect causes of non-adherence are two recommended measures to detect non-adherence and to design
interventions to improve the EN pattern of use. The community pharmacist, due to their closeness to
the patients and being the person in charge of the periodic dispensing of EN formulas, could play an
important role in improving the adherence of the patients to prolonged EN treatment.
5. Conclusions
Given the above, it was possible to conclude that more frequent and regular monitoring of patient
adherence to prolonged EN treatment is necessary as well as using measurement techniques to obtain
information on the causes of non-adherence to facilitate early intervention to optimize treatment
outcomes. Patient and/or caregiver education in the management of EN and the intervention of the
community pharmacist in monitoring patients can be key to improving the pattern of use of EN.
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